The aim of the registry is to evaluate Chinese real-World clinical outcomes in patients With AF using the WATCHMAN left Atrial appendage closure technology
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
1,050
WATCHMAN LAA occluder
Ling Tao
Xi’an, Shanxi, China
The composite primary endpoint of the stroke, systemic embolism, or cardiovascular or unexplained death
Time frame: 12 months post procedure
Bleeding
Life threatening or disabling, major bleeding and Minor bleeding
Time frame: Periprocedure and 1,5,6, 12, 24, 36, 48, 60 month post procedure
Vascular access-related complications
Haematoma at access site\<6 cm; Retroperitoneal haematoma;Arteriovenous fistula;Vascular surgical repair at catheter access sites;Pulmonary embolism;Ipsilateral deep vein thrombosis;Access site-related infection requiring intravenous antibiotics or extended hospitalization
Time frame: Periprocedure and 1,5,6, 12, 24, 36, 48, 60 month post procedure
Device-related complications
Device embolization; Device erosion;Clinically significant device interference with surrounding structure;Device thrombus;Device fracture;Device infection/endocarditis/pericarditis;Device perforation/laceration;Device allergy
Time frame: Periprocedure and 1,5,6, 12, 24, 36, 48, 60 month post procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.